Navigation Links
Measuring progesterone receptor expression to improve hormone-receptor-positive cancer management
Date:5/3/2012

American and Spanish researchers have found potential ways for doctors to improve the treatment of hormone receptor-positive breast cancer even if they lack access to costly multi-gene tests, as they report at the 4th IMPAKT Breast Cancer Conference.

Because breast cancer is a biologically and clinically varied disease, doctors aim to choose appropriate treatments based on the characteristics of each patient's individual tumor. In the past, this has been done using pathology-based biomarkers; however these do not capture the full diversity of cancers.

"In this context, tests based on multi-gene expression have been shown to provide valuable information beyond the pathology-based biomarkers," says Dr Aleix Prat from the University of North Carolina, Chapel Hill. "However, multi-gene tests are not readily available in most of the world due to cost, assay turnaround times and other logistic issues."

Dr Prat and colleagues addressed this problem by trying to improve the current pathology-based biomarkers to better represent data coming from a particular multi-gene test known as the PAM50 breast cancer intrinsic classifier.

"The PAM50 breast cancer intrinsic classifier identifies two major groups of hormonal receptor-positive breast cancer known as the Luminal A and Luminal B subtypes. These two molecular entities have different risks of relapse and responses to chemotherapy," Dr Prat said.

Alongside the development of this multi-gene assay, clinicians have devised pathology-based surrogate assays for the identification of both the Luminal A and Luminal B subtypes. "In the absence of multi-gene assays, the pathology-based assays are clinically valuable," Dr Prat explained. "However, we observed that the current pathology-based definitions of the Luminal A and Luminal B subtypes still show a 30-40% discordance rate compared to multi-gene tests such as the PAM50 breast cancer intrinsic classifier."

The researchers examined differences in gene expression patterns between Luminal A and Luminal B tumors using the PAM50 test. They also collected clinical-pathological features from 2,950 primary tumors across four independent studies. Using statistical methods, they tested the independent prognostic significance of those features.

They found that the expression of progesterone receptor was one of the most discriminatory molecules. "Addition of quantitative scoring of the progesterone receptor into the current pathology-based Luminal A definition appears to better identify the subgroup of patients that have an outstanding survival when treated with endocrine therapy alone, and therefore do not need systemic chemotherapy," Dr Prat said. "This subpopulation of patients is likely to represent around 30% of the patients with low-risk pathology-defined Luminal A tumors."

"Current pathology-based definitions of the Luminal A and Luminal B subtypes are valuable, but can be improved for the management of hormonal receptor-positive breast cancer," the researcher concluded. "We believe that we have an improvement based upon the progesterone receptor, and given that progesterone receptor is widely used, our improvement could be widely and quickly adopted, if further validated."

According to Dr Di Leo, Hospital of Prato, Italy, former IMPAKT Chair, this is an important study with practical implications, because it tells us that the evaluation of the progesterone receptor along with the evaluation of other biomarkers, such as the estrogen receptor, proliferation markers and c-erbB2, may be relevant to better define the biological profile of the tumor. "This is a critical step towards a personalized medicine approach in breast cancer. It will be important to test the progesterone receptors according to a standardized approach across the pathology departments. One potential concern, in fact, could be the use of different techniques for the progesterone receptors evaluation, which might lead to discordant results between different pathology labs."


'/>"/>

Contact: Vanessa Pavinato
media@esmo.org
European Society for Medical Oncology
Source:Eurekalert

Related biology news :

1. Measuring water from space
2. Measuring molecules to improve drug design
3. Measuring snow with a bucket, a windmill, and the sun?
4. Carbon measuring system to help mitigate climate change
5. Measuring intellectual disability
6. Epigentek Develops a New Method of Measuring Global DNA Methylation
7. SEA to conduct expedition dedicated to measuring plastic marine debris in the North Atlantic Ocean
8. Measuring protein movements with nanosecond resolution
9. Measuring the stability of organic waste
10. NSF awards $10M to develop computing techniques for measuring and analyzing child behavior
11. New paper examines approaches to measuring protein in foods in context of deadly adulterations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/9/2016)... , June 9, 2016  Perkotek an innovation leader in attendance control systems ... seamlessly log work hours, for employers to make sure the right employees are actually ... http://photos.prnewswire.com/prnh/20160609/377486LOGO ... ... ...
(Date:6/3/2016)... LONDON , June 3, 2016 /PRNewswire/ ... Transport Management) von Nepal ... ,Angebot und Lieferung hochsicherer geprägter Kennzeichen, einschließlich ... weltweit führend in der Produktion und Implementierung ... an der Ausschreibung im Januar teilgenommen, aber ...
(Date:6/2/2016)... 2016 Perimeter Surveillance & Detection ... Physical Infrastructure, Support & Other Service  The ... offers comprehensive analysis of the global Border Security ... revenues of $17.98 billion in 2016. Now: ... leader in software and hardware technologies for advanced video ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced ... this eBook by providing practical tips, tools, and strategies for clinical researchers. , ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is pleased ... received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval of ... Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods perform ...
Breaking Biology Technology: